Ian Braithwaite brings deep industry and therapeutic experience to his role overseeing project management and operational delivery for Worldwide Clinical Trial’s General Medicine business unit. He has full accountability for strategic development and execution of all projects conducted by these therapeutic areas, ranging from Immunology/Inflammatory Diseases (rheumatoid arthritis, lupus, psoriasis, IBD, asthma, COPD, etc.), Rare Diseases (for e.g., sickle cell disease, IPF, bullous pemphigoid, cutaneous T-cell lymphoma) and Oncology.
Dr. Braithwaite worked in clinical research for more than 26 years before joining Worldwide in 2015, including serving as Executive Vice President & GM, General Medicine at INC Research, and Global Therapeutic Area Head – General Medicine & Executive Director and Therapeutic Group Head Hematology/Oncology at PPD. Prior to joining the CRO industry, Ian was Director, Clinical Development at AstraZeneca Pharmaceuticals working primarily on Oncology and Immunology/Inflammatory Diseases. He began his career as a clinical research scientist at SmithKline & French after completing his academic studies.
Dr. Braithwaite obtained his Ph.D. in Pharmacology & Therapeutics from the University of Liverpool and Liverpool School of Tropical Medicine, United Kingdom.